



Beike Stem Cells for Multiple Sclerosis (MS)

What is the disease and how does it affect the body?

Multiple sclerosis (MS) is a common neurological disease and a major cause of disability, particularly affecting young adults. It is characterized by patches of damage occurring throughout the brain and spinal cord, with loss of myelin sheaths – the insulating material around nerve fibers that allows normal conduction of nerve impulses. Myelin is produced by specialized cells called oligodendrocytes that make myelin (oligodendrocytes) [1]. MS affects over two million people worldwide and shows a clear gender bias, with women being affected twice as frequently as men [2]. Etiology of MS is still unknown; it is generally thought that the disease will develop in genetically susceptible individuals as a result of an autoimmune response directed against components of myelin [2]. An environmental agent or event (virus, bacteria, chemicals, lack of sun exposure) has been hypothesized to act in concert with a specific genetic predisposition to result in immune dysfunction [3].

What happens to the body if the disease remains untreated?

MS affects principally young adults and leads to severe physical and cognitive impairment. MS follows a relapsing-remitting (RR) course in 85% and a primary progressive (PP) course in 15% of patients. In the majority of RR patients, secondary progression (SP) occurs after a median interval of 19 years, with persisting relapses in 40% of cases. Overall, MS patients lose the ability to walk independently at a median age of 63 years, but 1–3% of patients suffer from the malignant form of MS and reach this level of disability only in a few weeks or months [4, 5]. MS also leads to visual disturbances, loss of sensation, speech and swallowing dysfunction, bowel and bladder incontinence, erectile penile dysfunction.

What is the current treatment and the efficacy?

MS at present is incurable. We do not know the cause of the disease. Genetic factors culminating in autoimmune attack within the brain and spinal cord (central nervous system, CNS) is generally the accepted synthesis, but what such environmental factors may be remains obscure. Immune treatments are therefore routinely used, and these can reduce individual relapses both in severity (steroids, given acutely) and infrequency (interferons, glatiramer, and more recently various monoclonal antibodies, taken regularly). However, immune treatments have no impact on patients with progressive disability, Deficits relentlessly continue to accumulate [1].

How do stem cells help relieve the disease symptoms?

Recent research showed that stem cell treatment is beneficial in Multiple Sclerosis [1, 6-11].

Improvement:

Most MS patients treated with Beike stem cells, utilizing the combination of mesenchymal stem cell therapy and rehabilitation, showed visible signs of improvement: increasing muscle strength, decreasing muscle tone of spasticity, improving swallow ability, regaining eyesight, regaining motor development and coordination etc. However, when discussing improvements, it is important to remember that improvements might greatly differ from one patient to another due to many factors, such as patient's medical duration, severity, complication, physical condition, age and so on. Therefore, improvement cannot be guaranteed.

Mechanisms:

The mechanisms of mesenchymal stem cell for MS are probably based on the following aspects:

- (1) MSCs exert their immunomodulatory functions on numerous immune cells including T cells, B cell, NK cells and dendritic cells (DCs) [12]. MSC on one side induced peripheral T cell tolerance to myelin proteins thus reducing migration of pathogenic T cells to the CNS and, on the other side, homed themselves to the CNS where they preserved axons and reduced demyelination [6].
- (2) MSC can protect axons and improve neuronal survival [13-15], possibly via anti-apoptotic effects [16], anti-oxidant effects [17], or the release of trophic factors [18].
- (3) MSC can induce endogenous neurogenesis [19] and oligodendrogenesis [20-22].
- (4) MSC can decrease production of proinflammatory cytokines and chemokines [23].
- (5) MSCs also appear to reduce gliotic scar formation—gliosis representing a major barrier to spontaneous repair [24, 25].
- (6) Cord blood is an excellent source of hematopoietic stem cells in addition to mesenchymal stem cells and endothelial progenitor cells. Recent research from multiple organizations showed that hematopoietic stem cells help to modulate the immune system and modify the autoimmune response against the nerve cells. Hematopoietic stem cells differentiate into all types of blood cells thus help to renew the immune system.

Stem Cells and blood brain barrier (BBB): Based on the clinical data and research stem cells do cross the blood-brain-barrier when injected systemically thus IVs injections carry the same treatment effectiveness as compared to spinal injections. Moreover hematopoietic stem cells tend to work better when injected systemically.

References:

1. Scolding N, Adult stem cells and multiple sclerosis. *Cell Prolif.* 2011 Apr; 44 Suppl 1:35-8.
2. Payne N, Siatskas C, Bernard CC. The promise of stem cell and regenerative therapies for multiplesclerosis. *J Autoimmun.* 2008 Nov; 31 (3): 288-94.
3. Dymnt DA, Willer CJ, Scott B, Armstrong H et al. Genetic susceptibility to MS: a second stage analysis in Canadian MS families. *Neurogenetics.* 2001 Jul; 3 (3): 145-51.
4. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. *Brain.* 2006 Mar;129 (Pt3): 595-605.
5. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. *Brain.* 2006 Mar; 129 (Pt3): 606-16.
6. Uccelli A, Benvenuto F, Laroni A, Giunti D. Neuroprotective features of mesenchymal stem cells. *Best Pract Res Clin Haematol.* 2011 Mar; 24 (1): 59-64.
7. Connick P, Kolappan M, Patani R, et al. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. *Trials.* 2011 Mar 2; 12:62.
8. SKarussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S. Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral Sclerosis. *Arch Neurol.* 2010 Oct; 67 (10): 1187-94.
9. Slavin S, Kurkalli B G, Karussis D. The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders. *Clin Neurol Neurosurg.* 2008 Nov; 110 (9): 943-6.
10. Karussis D, Kassis I. The potential use of stem cells in multiple sclerosis: an overview of the preclinical experience. *Clin Neurol Neurosurg.* 2008 Nov; 110 (9): 889-96.
11. Uccelli A, Mancardi G. Stem cell transplantation in multiple sclerosis. *-Curr Opin Neurol.* 2010 Jun; 23 (3): 218-25.
12. Payne N, Siatskas C, Bernard C C. The promise of stem cell and regenerative therapies for multiple sclerosis. *J Autoimmun.* 2008 Nov; 31 (3): 288-94.
13. Gerdoni E, Gallo B, Casazza S, Musio S, Bonanni I, Pedemonte E, Mantegazza R, Frassoni F, Mancardi G, Pedotti R, Uccelli A. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. *Ann Neurol* 2007; 61 (3): 219–227.
14. Kassis I, Grigoriadis N, Gowda-Kurkalli B, Mizrachi-Kol R, Ben-Hur T, Slavin S, Abramsky O, Karussis D. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. *Arch Neurol* 2008; 65 (6): 753–761.
15. Zhang J, Li Y, Lu M, Cui Y, Chen J, Noffsinger L, Elias S B, Chopp M. Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. *J Neurosci Res* 2006; 84 (3): 587–595.
16. Crigler L, Robey R C ,Asawachaicharn A, Gaupp D, Phinney D G. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neurogenesis. *Exp Neurol* 2006; 198 (1): 54–64.
17. Lanza C, Morando S, Voci A, Canesi L, Principato M C, Serpero L D, Mancardi G, Uccelli A, Vergani L. Neuro protective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. *J Neurochem* 2009; 110 (5): 1674–1684.
18. Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, Scolding N. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. *Stem Cell Res* 2009; 3 (1): 63–70.
19. Munoz J R, Stoutenger B R, Robinson A P, Spees J L, Prockop D J. Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. *Proc Natl Acad Sci USA* 2005; 102 (50): 18171 –18176.
20. Bai L, Lennon D P, Eaton V, Maier K, Caplan A I, Miller S D, Miller R H. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. *Glia*2009; 57 (11): 1192–1203.
21. Akiyama Y, Radtke C, Kocsis J. Remyelination of the rat spinal cord by transplantation of identified bone marrow stromal cells. *J Neurosci* 2002; 22 (15): 6623–6630.
22. Rivera F J, Couillard-Despres S, Pedre X, Ploetz S, Caioni M, Lois C, Bogdahn U, Aigner L. Mesenchymal stem cells instruct oligod endrogenic fate decision on adult neural stem cells. *Stem Cells* 2006; 24 (10): 2209–2219.
23. Uccelli A, Prockop D J. Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? *Curr Opin Immunol.* 2010 Dec; 22 (6): 768-74.
24. Bai L, Lennon D P, Eaton V, Maier K, Caplan A I, Miller S D, Miller R H. Human bone marrow-derived mesenchymal stem cells induce Th2- polarized immune response and promote endogenous repair in animal models of multiple sclerosis. *Glia.* 2009 Aug 15; 57 (11): 1192-203.
25. Li Y, Chen J, Zhang C L, Wang L, Lu D, Katakowski M, Gao Q, Shen L H, Zhang J, Lu M, Chopp M. Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. *Glia* 49, 407–417. *Glia.* 2005 Feb; 49(3): 407-17.